Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment

Details

Serval ID
serval:BIB_7E19BA428430
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment
Journal
Intensive Care Med
Author(s)
Guery B. P., Arendrup M. C., Auzinger G., Azoulay E., Borges Sa M., Johnson E. M., Muller E., Putensen C., Rotstein C., Sganga G., Venditti M., Zaragoza Crespo R., Kullberg B. J.
ISSN
1432-1238 (Electronic)
ISSN-L
0342-4642
Publication state
Published
Issued date
02/2009
Volume
35
Number
2
Pages
206-14
Language
english
Notes
Guery, Benoit P
Arendrup, Maiken C
Auzinger, Georg
Azoulay, Elie
Borges Sa, Marcio
Johnson, Elizabeth M
Muller, Eckhard
Putensen, Christian
Rotstein, Coleman
Sganga, Gabriele
Venditti, Mario
Zaragoza Crespo, Rafael
Kullberg, Bart Jan
eng
Review
Intensive Care Med. 2009 Feb;35(2):206-14. doi: 10.1007/s00134-008-1339-6. Epub 2008 Oct 30.
Abstract
BACKGROUND: Invasive candidiasis and candidemia are frequently encountered in the nosocomial setting particularly in the intensive care unit (ICU). OBJECTIVE AND METHODS: To review the current management of invasive candidiasis and candidemia in non-neutropenic adult ICU patients based on a review of the literature and an European expert panel discussion. RESULTS AND CONCLUSIONS: Empiric and directed treatment for invasive candidiasis are predicated on the hemodynamic status of the patient. Unstable patients may benefit from broad-spectrum antifungal agents, which can be narrowed once the patient has stabilized and the identity of the infecting species is established. In stable patients, a more classical approach using fluconazole may be satisfactory provided that the patient is not colonized with fluconazole resistant strains or there has been recent past exposure to an azole (<30 days). In contrast, pre-emptive therapy is based on the presence of surrogate markers.
Keywords
Amphotericin B/*therapeutic use, Antifungal Agents/*therapeutic use, Bacteremia/*blood/*microbiology, Candida albicans/*isolation & purification, Candidiasis/*drug therapy/*microbiology, Fluconazole/*therapeutic use, Humans, *Intensive Care Units
Pubmed
Create date
29/04/2021 9:59
Last modification date
30/04/2021 5:38
Usage data